On March 20, 2024, Ramesh Kumar, PhD, a member of the board of directors since 2019 notified Ocugen, Inc. that he will not stand for re-election as a director of the Company upon the expiration of his current term, which expires at the Company?s 2024 Annual Meeting of Stockholders. Class I directors of the Board of Directors, of which Mr. Kumar is a member, terms expire at the Annual Meeting and are up for re-election at the Annual Meeting. Dr. Kumar?s refusal to stand for re-election was not the result of any disagreement with the Company on any matter relating to the Company?s operations, policies or practices.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.96 USD | +15.29% | +13.95% | +240.87% |
May. 15 | Ocugen Completes Dosing of Second Group in Stargardt Eye Therapy Safety and Efficacy Study | MT |
May. 14 | Transcript : Ocugen, Inc., Q1 2024 Earnings Call, May 14, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+240.87% | 504M | |
+29.77% | 49.46B | |
+1.00% | 42.58B | |
+50.47% | 42.49B | |
-5.26% | 29.09B | |
+13.68% | 26.61B | |
-22.99% | 18.64B | |
+8.22% | 13.16B | |
+32.41% | 12.55B | |
-1.62% | 11.98B |
- Stock Market
- Equities
- OCGN Stock
- News Ocugen, Inc.
- Ocugen, Inc. Announces Ramesh Kumar Will Not Stand for Re-Election as Director